Ultima Genomics Advances Large-Scale Proteomics Research
Ultima Genomics, a pioneering company in high-throughput sequencing, continues to enhance the landscape of scientific research. They have been selected to support groundbreaking proteomics studies that aim to unravel the complexities of human biology. At the forefront of these studies is the Regeneron Genetics Center (RGC), leveraging Ultima's UG 100™ sequencing platform.
Transforming Proteomics with Innovative Technology
The UG 100 sequencing platform is central to a large-scale study involving 200,000 blood serum samples. This extensive project is part of a much larger collaboration between RGC and Geisinger Health System, focusing on producing valuable insights through proteomics. In addition, this initiative aligns with the UK Biobank Pharma Proteomics Project, which aims to analyze 600,000 samples, pushing the frontier of proteomics studies as never before.
Mechanics Behind the Success
To achieve its ambitious goals, RGC plans to integrate the Olink Explore HT platform alongside Ultima's UG 100 technology. This combination is essential to meet the demands of extensive population-level research. The efficiency and scalability of the UG 100 platform have positioned Ultima Genomics as a leader in generating high-throughput data, essential for deciphering vast datasets entrenched in the field of proteomics.
Words from the CEO
Gilad Almogy, the founder and CEO of Ultima Genomics, expressed enthusiasm for these studies, stating, "We are pleased to continue supporting the ever-expanding large-scale proteomics studies that have the potential to drive important scientific and clinical insights. These studies build on the growing momentum we are seeing for population-scale proteomics and counting applications powered by Ultima's sequencing platform." His commitment highlights Ultima's pivotal role in the current scientific landscape.
About Ultima Genomics: A Vision for the Future
Ultima Genomics is committed to revolutionizing the way genomic information is harnessed and utilized. The company envisions a future where advances in biology translate into monumental improvements in human health and our understanding of biological systems. As the industry moves toward a new biological revolution, Ultima aims to address the escalating demand for comprehensive genomic information. They challenge the limitations imposed by conventional next-generation sequencing methods by lowering sequencing costs and enabling unprecedented data utilization.
Contact Information
For inquiries, please reach out to Vikki Herrera at Ultima Genomics by phone at 408-206-7009. For more details about Ultima’s revolutionary sequencing technologies, visit their official site at www.ultimagenomics.com.
Frequently Asked Questions
What is Ultima Genomics?
Ultima Genomics is a company focused on developing high-throughput sequencing technologies aimed at enhancing genomic research.
What studies is Ultima Genomics involved in?
They are currently supporting large-scale proteomics studies, including collaborations with the Regeneron Genetics Center.
What technology does Ultima use?
Ultima uses the UG 100™ sequencing platform, known for its scalability and efficiency.
How many samples are involved in the current studies?
The studies encompass 200,000 samples from the U.S. and an additional 600,000 samples from the UK.
Who can I contact for more information?
You can contact Vikki Herrera at Ultima Genomics for further inquiries.
